Pfizer ’s first-quarter revenue and earnings were down by nearly a third from a year ago on plummeting demand for its Covid-19 vaccine, but the results topped Wall Street expectations as the drugmaker searches for sales growth beyond pandemic products.
The drugmaker for the first three months of the year logged revenue of $18.28 billion, down 29% from a year ago but still well above Wall Street analyst estimates for $16.61 billion, according to analysts polled by FactSet.